(Legal Newsline) — The Federal Trade Commission (FTC) has approved a final
order settling charges that Mylan Inc.’s $7.2 billion acquisition of Swedish drug
maker Meda would be anticompetitive. The approval comes after a public comment
mandates that the companies divest two generic drugs – carisoprodol, a
treatment for muscle spasms, and felbamate, a treatment for refractory
believed without this divestment, the acquisition would harm consumers by
forcing them to pay higher prices. Additionally, the FTC charged it would
have eliminated competition between the two companies in the market for both
relinquish all rights and assets for its felbamate tablet to Alvogen Pharma US
Inc. and all U.S. marketing rights for carisoprodol, which will go back to
the owner of the drug, Indicus Pharma LLC. Indicus Pharma can now enter into an
agreement with a new marketing partner.
voted 3-0 to approve the final order.